FR2915102B1 - Utilisation d'un anticorps anti-cxcr4 pour le traitement du cancer - Google Patents

Utilisation d'un anticorps anti-cxcr4 pour le traitement du cancer

Info

Publication number
FR2915102B1
FR2915102B1 FR0702977A FR0702977A FR2915102B1 FR 2915102 B1 FR2915102 B1 FR 2915102B1 FR 0702977 A FR0702977 A FR 0702977A FR 0702977 A FR0702977 A FR 0702977A FR 2915102 B1 FR2915102 B1 FR 2915102B1
Authority
FR
France
Prior art keywords
cancer
treatment
cxcr4 antibody
cxcr4
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0702977A
Other languages
English (en)
Other versions
FR2915102A1 (fr
Inventor
Hamour Christine Klinguer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Pierre Fabre Medicament SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pierre Fabre Medicament SA filed Critical Pierre Fabre Medicament SA
Priority to FR0702977A priority Critical patent/FR2915102B1/fr
Priority to US12/451,025 priority patent/US20100150935A1/en
Priority to CA002683452A priority patent/CA2683452A1/fr
Priority to JP2010504784A priority patent/JP2010526044A/ja
Priority to PCT/FR2008/000553 priority patent/WO2008142303A2/fr
Priority to EP08787975A priority patent/EP2136840A2/fr
Publication of FR2915102A1 publication Critical patent/FR2915102A1/fr
Application granted granted Critical
Publication of FR2915102B1 publication Critical patent/FR2915102B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
FR0702977A 2007-04-23 2007-04-23 Utilisation d'un anticorps anti-cxcr4 pour le traitement du cancer Expired - Fee Related FR2915102B1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
FR0702977A FR2915102B1 (fr) 2007-04-23 2007-04-23 Utilisation d'un anticorps anti-cxcr4 pour le traitement du cancer
US12/451,025 US20100150935A1 (en) 2007-04-23 2008-04-18 Use of an anti-cxcr4 antibody in the treatment of cancer
CA002683452A CA2683452A1 (fr) 2007-04-23 2008-04-18 Utilisation d'un anticorps anti-cxcr4 pour le traitement du cancer
JP2010504784A JP2010526044A (ja) 2007-04-23 2008-04-18 癌治療のための抗ｃｘｃｒ４抗体の使用
PCT/FR2008/000553 WO2008142303A2 (fr) 2007-04-23 2008-04-18 Utilisation d'un anticorps anti-cxcr4 pour le traitement du cancer
EP08787975A EP2136840A2 (fr) 2007-04-23 2008-04-18 Utilisation d'un anticorps anti-cxcr4 pour le traitement du cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0702977A FR2915102B1 (fr) 2007-04-23 2007-04-23 Utilisation d'un anticorps anti-cxcr4 pour le traitement du cancer

Publications (2)

Publication Number Publication Date
FR2915102A1 FR2915102A1 (fr) 2008-10-24
FR2915102B1 true FR2915102B1 (fr) 2014-05-16

Family

ID=38448025

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0702977A Expired - Fee Related FR2915102B1 (fr) 2007-04-23 2007-04-23 Utilisation d'un anticorps anti-cxcr4 pour le traitement du cancer

Country Status (6)

Country Link
US (1) US20100150935A1 (fr)
EP (1) EP2136840A2 (fr)
JP (1) JP2010526044A (fr)
CA (1) CA2683452A1 (fr)
FR (1) FR2915102B1 (fr)
WO (1) WO2008142303A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2724409A1 (fr) * 2008-05-14 2009-11-19 Eli Lilly And Company Anticorps anti-cxcr4
GB201002238D0 (en) 2010-02-10 2010-03-31 Affitech As Antibodies
CN102884194B (zh) 2010-03-11 2015-07-22 健康研究股份有限公司 含增强免疫应答的Fc融合蛋白的方法和组合物
ES2758884T3 (es) 2011-06-24 2020-05-06 Stephen D Gillies Proteínas de fusión de inmunoglobulina a través de cadena ligera y métodos de uso de ellas
SI2776032T1 (sl) 2011-11-09 2018-12-31 Bristol-Myers Squibb Company Zdravljenje hematoloških malignih obolenj z anti-CXCR4 protitelesom
MX2017015811A (es) 2015-06-12 2018-04-10 Squibb Bristol Myers Co Tratamiento de cancer por bloqueo combinado de las trayectorias de señalizacion de muerte programada 1 (pd)-1 y receptor 4 de quimiocina c-x-c(cxcr4).
WO2017220989A1 (fr) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 et cytokines il-2
KR20200132915A (ko) 2018-03-13 2020-11-25 푼다시온 파라 라 인베스티가시온 바이오메디카 델 호스피탈 우니베르시타리오 라 파즈 암 면역요법을 위한, 활성화되고 확장된 자연 킬러 세포와 조합된 항-cxcr4 항체
US20210024873A1 (en) 2018-03-27 2021-01-28 Bristol-Myers Squibb Company Real-time monitoring of protein concentration using ultraviolet signal
WO2020172658A1 (fr) 2019-02-24 2020-08-27 Bristol-Myers Squibb Company Procédés d'isolement d'une protéine
EP3973274A1 (fr) 2019-05-23 2022-03-30 Bristol-Myers Squibb Company Méthodes de surveillance de milieu
US20230374064A1 (en) 2020-10-05 2023-11-23 Bristol-Myers Squibb Company Methods for concentrating proteins
WO2023173011A1 (fr) 2022-03-09 2023-09-14 Bristol-Myers Squibb Company Expression transitoire de protéines thérapeutiques

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080112950A1 (en) * 2002-11-07 2008-05-15 Lobo Peter I Naturally occurring IgM antibodies that bind lymphocytes
AR030631A1 (es) * 2000-09-29 2003-08-27 Abbott Lab Polipeptidos antiangiogenicos y metodos para inhibir la angiogenesis
US20050002939A1 (en) * 2002-12-23 2005-01-06 Albert Zlotnik Tumor killing/tumor regression using CXCR4 antagonists
US8329178B2 (en) * 2005-02-18 2012-12-11 Dana-Farber Cancer Institute, Inc. Antibodies against CXCR4 and methods of use thereof
SI2066351T1 (sl) * 2006-10-02 2016-02-29 E.R. Squibb & Sons, L.L.C. Humana protitelesa, ki vežejo cxcr4 in njihova uporaba

Also Published As

Publication number Publication date
US20100150935A1 (en) 2010-06-17
EP2136840A2 (fr) 2009-12-30
FR2915102A1 (fr) 2008-10-24
WO2008142303A3 (fr) 2009-01-22
JP2010526044A (ja) 2010-07-29
WO2008142303A2 (fr) 2008-11-27
CA2683452A1 (fr) 2008-11-27

Similar Documents

Publication Publication Date Title
FR2915102B1 (fr) Utilisation d'un anticorps anti-cxcr4 pour le traitement du cancer
FR2871696B1 (fr) Composition topique pour le traitement du psoriasis
FR20C1066I1 (fr) Pièges à gdf pour l'utilisation dans le traitment de l'anémie
FR22C1034I2 (fr) Rapports de médicament fixes pour le traitement des cancers hématopoïétiques et des troubles prolifératifs
FR2902324B1 (fr) Utilisation d'acide ellagique pour le traitement de la canitie
FR2907011B1 (fr) Utilisation de la citrulline pour le traitement des etats de denutrition
FR2912833B1 (fr) Panneau pour le traitement acoustique
FR2929946B1 (fr) Nouveaux anticorps anti-cd151 et leur utilisation pour le traitement du cancer
FR2920305B1 (fr) Utilisation d'un lysat de bifidobacterium species pour le traitement de peaux sensibles.
FR2867961B1 (fr) Instrument retractable de traitement pour un endoscope
FR2890306B1 (fr) Dispositif pour le traitement d'une poche vasculaire
FR13C0029I1 (fr) Compositions pour le traitement de troubles gastro-intestinaux
FR2887141B1 (fr) Orthese compressive tricotee du membre inferieur pour le traitement de l'insuffisance veineuse chronique
FR2898990B1 (fr) Utilisation de l'etat stationnaire d'automates cellulaires echangeant de l'energie pour modeliser des architectures sedimentaires
FR2897533B1 (fr) Agent oxydant pour le traitement des cheveux
FR2896422B1 (fr) Systeme de drainage pour le traitement de l'hydrocephalie
FR2906468B1 (fr) Utilisation de composes de la famille des avermectines pour le traitement de desordres dermatologiques
FR2902320B1 (fr) Utilisation de butylated hydroxyanisole pour le traitement de la canitie
FR2920301B1 (fr) Utilisation d'une association hesperidine et microorganisme pour le traitement de la secheresse des matieres keratiniques.
FR2899918B1 (fr) Laboratoire mobile pour l'analyse d'agents pathogenes
ITRM20050478A1 (it) Apparato per l'applicazione contemporanea della carbossiterapia e della mesoterapia.
FR2910813B1 (fr) Nouvelle utilisation therapeutique pour le traitement des leucemies
FR2901166B1 (fr) Dispositif pour l'arrachage de goupiles taraudees
FR2868307B1 (fr) Utilisation de beta-endorphine pour le traitement des rides
FR2924593B1 (fr) Plaque osseuse pour le traitement de l'extremite inferieure du cubitus

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 10

PLFP Fee payment

Year of fee payment: 11

PLFP Fee payment

Year of fee payment: 12

ST Notification of lapse

Effective date: 20191206